RBC Bioscience

RBC Bioscience FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of RBC Bioscience (6848.TWO) as of Nov 5, 2026 is 211.48 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 104.88 % — a change of 101.63% (higher).

FCF Conversion

211.48 %

YoY

101.63%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of RBC Bioscience is 2024 211.48 % . FCF Conversion Rate (FCF/EBITDA) of RBC Bioscience was 2023 104.88 % . It decreases by 101.63% higher compared to the previous year.

The RBC Bioscience FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-482.63 TWD
Jan 1, 2019
214.93 TWD
Jan 1, 2020
61.50 TWD
Jan 1, 2021
-1,654.88 TWD
Jan 1, 2022
-91.16 TWD
Jan 1, 2023
104.88 TWD
Jan 1, 2024
211.48 TWD
The RBC Bioscience FCF Conversion history
YEARFCF ConversionYoY
211.48 %+101.63%
104.88 %-215.05%
-91.16 %-94.49%
-1,654.88 %-2,790.85%
61.50 %-71.39%
214.93 %-144.53%
-482.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

FCF Conversion Rate (FCF/EBITDA) of RBC Bioscience is 211.48 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of RBC Bioscience changed from 104.88 % to 211.48 %, representing a 101.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — RBC Bioscience

All Key Metrics — RBC Bioscience